Lilly Pulls COVID-19 Antibody Treatment From EU Review
Concern Over Resistance Of Delta Variant May Have Played A Part
While Lilly's antibody combination of etesevimab and bamlanivimab is still going strong in the US, the company has lost out to Roche's Ronapreve in the EU.
You may also be interested in...
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.